Samantha R. Pierson

Samantha R. Pierson

Auto-generated profile, based on publicly available information

Samantha R. Pierson

University of Iowa Carver College of Medicine

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 August 2024 in Molecular Psychiatry
Verified
Journal Article
Closed access
PDF file
SPSamantha R. Pierson
Samantha R. Pierson
KFKimberly L. Fiock
Kimberly L. Fiock
RWRuixiang Wang
Ruixiang Wang
NBNagalakshmi Balasubramanian
Nagalakshmi Balasubramanian
JRJessica Reinhardt
Jessica Reinhardt
CMCatherine A. Marcinkiewcz
Catherine A. Marcinkiewcz

8 May 2024 in Psychiatry Research
Verified
Journal Article
Closed access
LKLouis J. Kolling
Louis J. Kolling
KKKanza Khan
Kanza Khan
RWRuixiang Wang
Ruixiang Wang
SPSamantha R. Pierson
Samantha R. Pierson
BHBenjamin D. Hartman
Benjamin D. Hartman
CMCatherine A. Marcinkiewcz
Catherine A. Marcinkiewcz

25 February 2021 in Behavioral Neuroscience
Verified
Journal Article
Closed access
JFJohn H. Freeman
John H. Freeman
SFSean J. Farley
Sean J. Farley
SPSamantha R. Pierson
Samantha R. Pierson
Previous studies found that inactivation of the central amygdala (CeA) severely impaired acquisition of cerebellum-dependent delay eye-blink conditioning (EBC) in male rats and rabbits. Sex differences in EBC and the effects of stress on EBC have been reported and might be related to sex differences in amygdala modulation of cerebellar learning. The current study examined the effects of CeA inactivation with muscimol on acquisition and retention of EBC in female rats. Like male rats, CeA inactivation in female rats severely impaired EBC acquisition and retention. Comparison of the female data with previously published data from males indicates no substantive sex differences in the effects of CeA inactivation on acquisition or retention of EBC. The results indicate that amygdala modulation of cerebellar learning is not sex-specific. (PsycInfo Database Record (c) 2021 APA, all rights reserved).

30 May 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
RWRuixiang Wang
Ruixiang Wang
KKKanza Khan
Kanza Khan
Nagalakshmi BalasubramanianNagalakshmi Balasubramanian
Nagalakshmi Balasubramanian
TJThomas James
Thomas James
SPSelvakumar Govindhasamy Pushpavathi
Selvakumar Govindhasamy Pushpavathi
CMCatherine A. Marcinkiewcz
Catherine A. Marcinkiewcz
Social interaction is a core component of motivational behavior that is perturbed across multiple neuropsychiatric disorders, including alcohol use disorder (AUD). Positive social bonds are neuroprotective and enhance recovery from stress, so reduced social interaction in AUD may delay recovery and lead to alcohol relapse. We report that chronic intermittent ethanol (CIE) induces social avoidance in a sex-dependent manner and is associated with hyperactivity of serotonin (5-HT) neurons in the dorsal raphe nucleus (DRN). While 5-HT DRN neurons are generally thought to enhance social behavior, recent evidence suggests that specific 5-HT pathways can be aversive. Using chemogenetic iDISCO, the nucleus accumbens (NAcc) was identified as one of 5 regions that were activated by 5-HT DRN stimulation. We then employed an array of molecular genetic tools in transgenic mice to show that 5-HT DRN inputs to NAcc dynorphin neurons drive social avoidance in male mice after CIE by activating 5-HT 2C receptors. NAcc dynorphin neurons also inhibit dopamine release during social interaction, reducing the motivational drive to engage with social partners. This study reveals that excessive serotonergic drive after chronic alcohol can promote social aversion by inhibiting accumbal dopamine release. Drugs that boost brain serotonin levels may be contraindicated for individuals with AUD.

23 November 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
SPSamantha Pierson
Samantha Pierson
KFKimberly L. Fiock
Kimberly L. Fiock
RWRuixiang Wang
Ruixiang Wang
Nagalakshmi BalasubramanianNagalakshmi Balasubramanian
Nagalakshmi Balasubramanian
JRJessica Reindhardt
Jessica Reindhardt
CMCatherine A. Marcinkiewcz
Catherine A. Marcinkiewcz
Protein aggregation in brainstem nuclei is thought to occur in the early stages of Alzheimer’s disease (AD), but its specific role in driving prodromal symptoms and disease progression is largely unknown. The dorsal raphe nucleus (DRN) contains a large population of serotonin (5-hydroxytryptamine; 5-HT) neurons that regulate mood, reward-related behavior, and sleep, which are all disrupted in AD. We report here that tau pathology is present in the DRN of individuals 54-80 years old without a known history of dementia and was found at higher frequency than α-synuclein and TDP-43. Most AD cases had tau pathology in the DRN (90%), whereas only a subset contained TDP-43 or α-synuclein, but not both (30%). To evaluate how early tau pathology impacts behavior, we overexpressed human P301L-tau in the DRN of mice and observed depressive-like behaviors and hyperactivity without any deficits in spatial memory. Tau pathology was predominantly found in neurons relative to glia and colocalized with a significant proportion of Tph2-expressing neurons in the DRN. 5-HT neurons were also hyperexcitable in P301L-tau DRN mice, and there was an increase in the amplitude of excitatory post-synaptic currents (EPSCs), suggestive of increased glutamatergic transmission. Moreover, astrocytic density was elevated in the DRN and accompanied by an increase in IL-1α and Frk expression, which is indicative of inflammation. Additionally, tau pathology was detected in axonal processes in the thalamus, hypothalamus, amygdala, and caudate putamen and a significant proportion of this tau pathology colocalized with the serotonin reuptake transporter (SERT), suggesting that tau may spread in an anterograde manner to regions outside the DRN. Together these results indicate that tau pathology accumulates in the DRN in a subset of individuals over 50 years and may lead to behavioral dysregulation, 5-HT neuronal dysfunction, and activation of local astrocytes which may be prodromal indicators of AD.

6 April 2026 in The Cleft Palate Craniofacial Journal
Verified
Journal Article
Closed access
BABrian T. Andrews
Brian T. Andrews
MZMario Zanaty
Mario Zanaty
SPSamantha R. Pierson
Samantha R. Pierson
KFKimberly L. Fiock
Kimberly L. Fiock
MHMatthew A. Howard
Matthew A. Howard
TYTerry C. Yin
Terry C. Yin
Objective: Glymphatic dysfunction contributes to CNS pathobiology, including neurodegeneration. We hypothesized that vascularized lymph node transfer (VLNT) augments CSF-interstitial solute clearance and could be translated as a surgical therapy analogous to lymphedema surgery. Design: Twenty Long-Evans rats were randomized to 3 arms: (1) Craniectomy Control (hemi-craniectomy; VLNT sampled in situ, nontransposed), (2) VLNT Control (intact calvarium; VLNT without craniectomy), and (3) Experimental (hemi-craniectomy + VLNT). One week postsurgery, Evans Blue dye (EBD) was injected into the cisterna magna; at 4 h, right/left cerebrum and cerebellum lysates underwent spectrophotometry at 608 nm. VLNT viability was verified by podoplanin (PDPN) immunohistochemistry. Main Outcome Measure(s): Two-way ANOVA showed significantly reduced EBD in Experimental vs controls: left hemisphere vs Craniectomy Control P = .0011 and vs VLNT Control P = .0200; cerebellum vs both controls P < .0001. The right hemisphere was lower vs Craniectomy Control ( P = .0255) and not different from VLNT Control ( P = .3878). VLNT-tissue lysates were higher in Experimental than Craniectomy Control ( P = .0028) and VLNT Control ( P = .0289), consistent with active lymphatic uptake. PDPN staining confirmed robust lymphatic endothelial labeling in cross-sectional and longitudinal planes. Results: VLNT significantly enhances putative glymphatic efflux following decompressive craniectomy, recapitulating the therapeutic principle of lymphatic bypass in lymphedema. Conclusion: These proof-of-concept data support VLNT as a candidate surgical intervention for glymphatic insufficiency and neurodegenerative (ND)-relevant proteostasis/clearance failure. Future studies will optimize timing, node vascularization strategies, and longitudinal outcome measures.